Savient Files Citizen Petition to Block Generic Oxandrin

Drug Industry Daily
KEYWORDS labeling / Patents
A A

Savient Pharmaceuticals has filed its second citizen petition with the FDA in two years to block generic versions of its anti-weight-loss drug Oxandrin.

To View This Article:

Login

Subscribe To Drug Industry Daily